Market Overview
The European chronic Disease Management Market is anticipated to reach USD 1.3 billion in 2025, driven by the rising prevalence of chronic conditions, aging demographics, and the accelerated transition towards value-based, digitally enabled healthcare across the region. The market is expected to expand at a robust compound annual growth rate (CAGR) of 11.9% from 2025 to 2034, reaching a projected value of USD 3.7 billion by 2034.
Growth is fueled by the widespread integration of remote patient monitoring (RPM) platforms, the strategic adoption of artificial intelligence (AI) and predictive analytics, stringent data protection (GDPR) and medical device regulations, and increasing demand for cost-effective, patient-centric care models. Furthermore, expanding applications across Diabetes, Cardiovascular Diseases (CVD), and Chronic Respiratory Diseases, coupled with the need for interoperable solutions and comprehensive population health management, are expected to significantly accelerate market expansion.
The European chronic care landscape is evolving from episodic, facility-based interventions to continuous, data-driven management ecosystems. A pivotal trend is the strategic convergence of disease-specific digital therapeutics and telehealth, where CDM platforms are transforming into integrated care delivery hubs. These hubs enable personalized monitoring, virtual consultations, and automated interventions, which are crucial for meeting efficiency targets and patient self-management goals under value-based reimbursement models. This integration empowers proactive health management and facilitates real-time clinical decision support for complex conditions like heart failure and COPD.
Concurrently, CDM solution providers are embedding sophisticated analytics and clinical decision support (CDS) tools, offering risk stratification and personalized care pathway automation as core features, making data intelligence a foundational element of the chronic care value chain. The fusion of AI with population health platforms is also gaining prominence, optimizing resource allocation and preemptively identifying high-risk patient cohorts across Europe's diverse healthcare systems.
The market's expansion is underpinned by significant opportunities in personalized and preventive chronic care, particularly for managing multimorbidity and supporting integrated care networks that demand seamless coordination and reliability. Providers and Payers have emerged as primary adopters, leveraging CDM technology for scalable management of chronic populations, medication adherence programs, and post-acute care coordination, which are seeing rapid utilization growth.
Moreover, the continuous development of novel, integrated service models, including remote monitoring services and AI-driven insights, is creating new avenues for dynamic care experiences that are highly responsive and engaging. These innovations are poised to address critical challenges in fragmentation-prone care delivery, such as oncology follow-up and mental health comorbidity management, providing outcome-based guarantees essential for sustainable healthcare across the EU.
Europe Chronic Disease Management Market: Key Takeaways
- Europe Market Size Insights: The Europe Chronic Disease Management Market is projected to be valued at USD 1.3 billion in 2025. It is expected to witness subsequent growth in the upcoming period, reaching a projected value of USD 3.7 billion in 2034.
- The Europe Market Growth Rate: The market is growing at a CAGR of 11.9 percent over the forecasted period from 2025 to 2034.
- Key Drivers: Growth is primarily fueled by the rising burden of chronic diseases and aging populations, the integration of RPM and telehealth solutions, supportive EU and national digital health policies, and stringent data compliance and cybersecurity requirements.
- Competitive Landscape: The market is highly competitive and features a mix of global medtech and health IT giants (Philips, Siemens Healthineers), specialized digital health and DTx providers, hyperscale cloud platforms (AWS, Google, Microsoft), and regional health system integrators.
- Segment Insights: Within offerings, Solutions, particularly RPM and Disease-Specific Platforms, are the largest component, while Diabetes Mellitus remains the dominant indication segment due to high prevalence and a mature ecosystem of digital tools.
Europe Chronic Disease Management Market: Use Cases
- Integrated CHF Management for a Regional Health Network: A hospital group uses a dedicated CHF platform integrated with RPM (connected scales, blood pressure cuffs) and telehealth to manage heart failure patients post-discharge. AI-driven analytics flag weight gain trends, triggering automated nurse alerts and virtual consultations, drastically reducing 30-day readmission rates.
- National Diabetes Prevention & Management Program: A public payer partners with a vendor to deploy a diabetes management platform combined with mHealth apps and connected glucose monitors. The program offers personalized coaching, dietary logging, and integrates data into primary care EHRs, improving HbA1c control at a population level and demonstrating clear ROI.
- Oncology Survivorship Care via Hybrid Platform: A cancer center implements a hybrid oncology CDM platform offering teleconsultation for follow-ups, a patient app for symptom tracking (PROs), and analytics for monitoring long-term effects. This ensures continuity of care, reduces unnecessary clinic visits, and improves quality of life for survivors.
- COPD Exacerbation Prediction with IoT Sensors: A respiratory care provider utilizes an IoT-enabled platform with smart inhalers and home spirometers. ML algorithms analyze usage patterns and lung function data to predict exacerbation risk, enabling pre-emptive interventions by a remote monitoring service team, preventing emergency hospitalizations.
- Value-Based Contract Enablement for a Private Insurer: A private insurer deploys a comprehensive population-health analytics platform with risk stratification tools to identify high-cost members with multiple chronic conditions. It then offers tailored disease management programs (e.g., for hypertension and depression comorbidity) to provider networks, sharing data and outcomes to manage value-based contracts effectively.
Europe Chronic Disease Management Market: Stats & Facts
World Health Organization (WHO / WHO Europe)
- The four major non-communicable diseases (CVD, cancer, diabetes, and chronic respiratory diseases) account for nearly 75% of all deaths in the WHO European Region.
- NCDs remain the leading cause of mortality across the region.
- Chronic respiratory diseases cause almost 400,000 deaths annually in the region, with about 81.7 million people currently living with chronic respiratory conditions.
Eurostat / European Commission
- EU countries recorded about 1.68 million deaths from circulatory system diseases in 2022, representing 32.7% of all deaths.
- Cancer is responsible for roughly 22.3% of all EU deaths.
- The EU’s standardised death rate for circulatory diseases is approximately 336.4 per 100,000 residents.
- Respiratory diseases account for around 6.1% of all deaths across the EU.
OECD (Health at a Glance: Europe and associated publications)
- OECD reporting highlights diabetes and multiple chronic conditions as leading contributors to long-term care demand in European health systems.
- Routine diabetes care and monitoring dropped significantly across Europe during the pandemic years, according to OECD indicators.
- OECD identifies improved prevention and stronger primary care–based chronic disease management as central to reducing avoidable NCD burden across Europe.
International Diabetes Federation (IDF Europe)
- Diabetes prevalence in the WHO European Region is estimated at close to 9.8%, representing about 66 million people.
- Diabetes prevalence and absolute case numbers in Europe are projected to grow by roughly 10% by 2050.
- A large proportion of diabetes cases in the region remain undiagnosed, increasing the potential load on chronic disease management systems.
European Cancer Information System (ECIS) / European Commission – Cancer Burden
- Estimated new cancer cases in the EU reached nearly 2.7 million in 2022.
- Estimated cancer deaths in the EU were about 1.3 million in 2022.
- New cancer incidence has increased by more than 2% between 2020 and 2022.
- EU cancer case projections indicate sharp increases by 2040, largely driven by ageing and lifestyle factors.
World Bank – Europe (Health System & NCD Burden Assessments)
- NCDs represent the majority of all deaths across Europe in World Bank regional analyses.
- Premature NCD mortality has been declining steadily across Europe, but substantial differences remain between Western, Eastern, and Southern regions.
European Environment Agency (EEA) – Cardiovascular Disease Burden
- More than six million new cardiovascular disease cases occur annually in the EU.
- Over 1.7 million deaths from circulatory diseases occur each year, keeping CVD the top cause of mortality in Europe.
European Heart Network / World Heart Federation (Europe CVD Burden)
- Cardiovascular disease affects more than 60 million people across Europe.
- CVD leads to approximately 1.7–1.8 million deaths each year in the EU.
- Annual economic costs related to cardiovascular disease in Europe exceed €280 billion.
Lancet – Europe NCD & CVD Burden Studies
- A major Lancet analysis estimated that about 11.4 million cardiovascular deaths in Europe between 1995 and 2020 were avoidable with better prevention and chronic-care systems.
WHO / European Respiratory & COPD Burden
- Chronic respiratory diseases are the sixth leading cause of death in the European Region.
- Approximately 80% of chronic respiratory disease deaths in Europe are attributed to COPD.
- COPD prevalence is projected to rise significantly by 2050, with a notable increase among women.
NHS Digital / England – Long-Term Conditions (as part of Europe’s key national datasets)
- The Health Survey for England shows that about 41% of adults live with at least one longstanding illness or chronic condition.
- Estimates indicate that around 25 million people in England have at least one long-term condition, and more than 13 million live with multiple conditions.
- People with long-term conditions account for a disproportionately high share of GP visits, prescription use, and hospital activity.
European Academic Studies – Multimorbidity and Ageing
- Research shows absolute chronic disease burden among older Europeans has risen steadily from 1990 to 2019, with cardiovascular diseases and multimorbidity being major drivers.
- Projections for COPD and other chronic diseases indicate substantial increases in prevalence and absolute patient numbers in the coming decades, emphasizing the need for expanded chronic-disease management capacity.
Europe Chronic Disease Management Market: Market Dynamics
Driving Factors in the Europe Chronic Disease Management Market
Convergence of Telehealth, RPM, and Data Analytics into Unified Platforms
A major trend is the rapid market shift from standalone point solutions to integrated platforms that combine telehealth/teleconsultation, RPM data ingestion, and advanced analytics. European health systems and providers are demanding unified workflows to avoid clinician fatigue from multiple logins and to gain a holistic patient view. This convergence is critical for managing multimorbidity, where data from different conditions must be correlated. Regulatory pushes for interoperability (e.g., via the European Health Data Space - EHDS) and value-based care contracts further accelerate investment in platforms that can aggregate and analyze data from diverse sources, including wearables, EHRs, and patient-reported outcomes, to drive coordinated action and measure results.
Proliferation of Indication-Specific Digital Therapeutics and Connected Devices
Another powerful driver is the burgeoning ecosystem of CE-marked Digital Therapeutics (DTx) and medical-grade connected devices for specific chronic conditions. Regulated DTx for diabetes self-management, insomnia, or depression are being prescribed and reimbursed in markets like Germany and France. This formalizes digital interventions as part of standard care. Simultaneously, connected insulin pens, smart inhalers, and cardiac implantable monitors generate continuous, clinically actionable data. CDM platforms that seamlessly integrate these prescribed digital tools into care pathways create significant value, enabling closed-loop management and providing robust evidence for outcomes-based reimbursement.
Restraints in the Europe Chronic Disease Management Market
Unsustainable Burden of Chronic Disease and Demographic Shift
One of the most powerful, underlying growth drivers is the demographic and epidemiological reality: Europe's aging population is leading to a steep rise in the prevalence of multimorbidity. Healthcare systems are financially strained by the costs of hospitalizations, emergency care, and long-term complications associated with poorly managed chronic conditions. This crisis creates an urgent, non-negotiable imperative for cost-effective management tools. Payers (both public and private) and providers are increasingly compelled to invest in CDM solutions as strategic assets for preventive care, improving medication adherence, and enabling early intervention, directly targeting the reduction of high-cost acute episodes.
Accelerating Digital Health Policy and Reimbursement Evolution
The accelerated evolution of supportive digital health policies and reimbursement frameworks across Europe is a major growth catalyst. Initiatives like the EHDS, national digital health strategies (e.g., in the Nordics, DACH, UK), and the creation of new reimbursement codes for remote monitoring and digital health applications (DiGAs in Germany, DTx in France) are reducing adoption barriers. These policies are actively funding pilot programs, clarifying data governance, and creating sustainable payment pathways. This environment de-risks investment for providers and stimulates innovation from vendors, fueling widespread adoption of CDM platforms as core infrastructure for modern healthcare delivery.
Opportunities in the Europe Chronic Disease Management Market
Advanced AI/ML for Predictive and Prescriptive Analytics
The application of advanced AI and machine learning beyond basic analytics represents a significant high-value opportunity. The next frontier involves prescriptive analytics that not only predict a patient's risk but also recommend specific, personalized interventions with estimated probabilities of success. Furthermore, AI for operational optimization, predicting no-shows, optimizing staff schedules for remote monitoring centers, or automating prior authorizations for chronic therapies can deliver substantial efficiency gains. Vendors that can embed these sophisticated, explainable AI capabilities into their platforms will capture premium opportunities, especially with large payers and integrated delivery networks focused on population health management.
Expansion into Complex Chronic Indications and Comorbidity Management
While diabetes and CVD are established markets, substantial growth opportunities lie in expanding robust CDM solutions into more complex and underserved chronic indications. This includes oncology survivorship care, chronic kidney disease (CKD) management, and especially integrated mental and physical health comorbidity (e.g., diabetes and depression). Platforms that can handle the intricate, longitudinal care pathways, polypharmacy, and multidisciplinary coordination required for these conditions will address critical gaps in care. The development of indication-specific modules within broader platforms, or best-of-breed solutions that interoperate, presents a major avenue for innovation and market capture.
Trends in the Europe Chronic Disease Management Market
High Integration Complexity and Persistent Interoperability Hurdles
A major restraint is the significant technical and operational complexity involved in integrating new CDM solutions into Europe's fragmented and legacy-heavy health IT landscape. Ensuring seamless interoperability with multiple, often outdated EHR systems, regional health information exchanges, and medical devices from various manufacturers requires substantial customization, ongoing maintenance, and vendor cooperation. These challenges are amplified by the lack of universal data standards and varying implementation of FHIR across the EU. For healthcare organizations, this results in high upfront and ongoing costs, extended deployment timelines, and clinician frustration, which can stall or derail projects, particularly for smaller providers with limited IT resources.
Fragmented Reimbursement and Challenges in Demonstrating Tangible ROI
Despite progress, reimbursement for digital chronic care services remains fragmented and inconsistent across and within European countries. While some activities (e.g., a telehealth consultation) may be reimbursed, the ongoing costs of platform licensing, data integration, and clinical staff time for monitoring are often not fully covered. This creates financial uncertainty for providers. Linked to this is the challenge of demonstrating clear, short-term Return on Investment (ROI) in hard financial terms. While improved outcomes and patient satisfaction are evident, translating them into immediate cost savings for a specific budget holder can be difficult, making procurement decisions slower and more risk-averse, particularly in publicly funded systems.
Europe Chronic Disease Management Market: Research Scope and Analysis
By Offering Analysis
Solutions are projected to constitute the dominant and core value segment of the European CDM market. This category encompasses the essential software and technology platforms. Disease-Specific Software (e.g., dedicated Diabetes, CHF/CVD, COPD Platforms) provides tailored workflows, guidelines, and device integrations for optimal condition management. Remote Patient Monitoring (RPM) Platforms form the data backbone, ingesting and managing streams from connected devices. Telehealth/Teleconsultation Platforms enable virtual care delivery.
Analytics & Population-Health Platforms with Clinical Decision Support and Risk Stratification turn data into actionable intelligence. Mobile Apps & Patient Engagement Tools (mHealth) are critical for adherence and self-management. Integration & EHR Connectors are non-negotiable components for realizing value in real-world clinical settings. The demand for these solutions is driven by the need to operationalize digital-first chronic care models.
The Services segment is the fastest-growing component, reflecting the market's maturation. As solutions become more powerful, their implementation and effective use require deep expertise. Disease Management Programs offered by vendors provide turnkey clinical operations.
Remote Monitoring Services involve clinical staff monitoring data feeds and acting on alerts. Consulting & Implementation services are vital for navigating complex health system IT environments and change management. Training & Support ensure ongoing clinician and patient engagement. This shift towards solution-and-service bundles indicates a market moving from selling software to delivering measurable health outcomes.
By Deployment Type Analysis
Cloud-based deployment is expected to be the unequivocally dominant and fastest-growing model, projected to hold over 65% market share by 2034. Its technological and economic advantages elastic scalability, reduced upfront capital expenditure (CapEx), automated software updates, and built-in geo-redundant disaster recovery, are perfectly aligned with the dynamic, data-intensive needs of modern value-based healthcare.
The subscription-based Software-as-a-Service (SaaS) model transforms large capital outlays into predictable operating expenses, a critical factor for budget-constrained public health systems and smaller clinics. Major cloud providers with sovereign EU-based data regions (e.g., AWS EU Frankfurt, Microsoft Azure Germany, Google Cloud Zürich) not only guarantee compliance with GDPR and local data residency laws but also offer advanced, pre-certified security frameworks (ISO 27001, ISO 27017) that individual healthcare organizations would struggle to implement independently.
This model effectively democratizes advanced chronic care management, enabling a solo primary care practice or a regional ambulatory network to access the same enterprise-grade CDM capabilities, including AI analytics, telehealth, and population health tools, as a large university hospital, via a scalable pay-per-use subscription. The inherent agility of the cloud also supports rapid innovation, allowing vendors to deploy new features, therapeutic modules, and compliance updates seamlessly across their entire European customer base.
By Indication Analysis
Diabetes Mellitus remains the largest and most dynamic indication segment, accounting for approximately 30-35% of the solution-focused market revenue. It is characterized by a mature, innovation-rich ecosystem of connected devices, including Continuous Glucose Monitors (CGMs), smart insulin pens/pumps, and connected glucose meters that generate a continuous, actionable data stream. The condition has a strong, well-established evidence base demonstrating that digital interventions improve glycemic control (HbA1c), reduce hypoglycemic events, and enhance quality of life. This evidence directly supports reimbursement arguments.
Furthermore, diabetes management inherently requires frequent daily decision-making by the patient, leading to high patient motivation for self-management tools. Modern CDM solutions for diabetes are highly sophisticated platforms that integrate real-time CGM data with AI-driven pattern recognition (predicting highs/lows), automated insulin dosing calculators, personalized dietary and activity logging, and seamless data sharing with clinicians.
The market is further segmented into Type 1 (focused on advanced device integration) and Type 2 (focused on lifestyle modification and medication adherence), with digital prevention programs for pre-diabetes representing a high-growth adjacent segment.
Cardiovascular Diseases (CVD), and particularly Heart Failure (HF), represent another dominant, high-acuity, and high-value segment. The management of HF is highly protocolized and relies on the daily monitoring of key vitals such as weight, blood pressure, and symptoms, making it an ideal use case for Remote Patient Monitoring (RPM). CDM platforms for CVD are mission-critical for health systems aiming to reduce 30-day readmission rates, a key quality and financial metric tied to value-based care contracts.
By Technology Analysis
Wearables & Connected Devices and the underlying Internet of Things (IoT) & Sensor technologies form the indispensable data acquisition layer of the CDM ecosystem. This sector is moving beyond consumer fitness trackers to a proliferation of prescribed, medical-grade devices. These include continuous glucose monitors (CGMs), connected blood pressure cuffs and weight scales, smart inhalers, adhesive ECG patches, and implantable cardiac monitors.
These devices provide a continuous, objective, and passive stream of clinical-grade data, moving management from episodic, snapshot-in-time clinic visits to a longitudinal, real-time understanding of a patient's health status. The integration of this data via Bluetooth, cellular (IoT), or home hubs into CDM platforms is a core technical function and a primary source of value creation.
AI / ML & Predictive Analytics and Clinical Decision Support (CDS) systems constitute the intelligence and insights layer that transforms raw data into actionable clinical knowledge. This is where the highest value creation and competitive differentiation occur. Machine Learning (ML) models are trained on vast, de-identified datasets to identify subtle patterns and predict events such as heart failure hospitalization, hypoglycemia, or COPD exacerbation days before they occur.
By End User Analysis
Providers are the primary clinical end-users, directly responsible for care delivery. Hospitals, Physician Groups & Integrated Delivery Networks (IDNs) use CDM for care transition management, virtual wards, and specialist-led chronic disease clinics. Ambulatory Care Centers and Primary Care leverage these tools for population health management, preventive screening, and longitudinal care of their registered patient panels. Home Healthcare Agencies are natural adopters, using RPM and telehealth to monitor patients remotely, improving efficiency and visit scheduling. Pharmaceutical & Medtech Companies are increasingly partnering with or deploying CDM platforms to support patient adherence, gather real-world evidence, and differentiate their therapeutic offerings.
Payers are the primary economic and strategic end-users, focused on cost containment and member health. Public Payers (National/Regional Health Services) deploy CDM strategies for population-level disease prevention and management, aiming to improve system-wide outcomes and sustainability. Private Insurers use CDM for risk-based member segmentation, offering value-added wellness programs, and managing high-cost claimants. Employer-Sponsored Funding entities are emerging as a growing segment, investing in CDM solutions to improve employee health, reduce absenteeism, and control corporate healthcare spend.
The Europe Chronic Disease Management Market Report is segmented on the basis of the following
By Offering
- Solutions
- Disease-Specific Software
- Diabetes Management Platforms
- CHF/CVD Platforms
- COPD Platforms
- Remote Patient Monitoring (RPM) Platforms
- Telehealth / Teleconsultation Platforms
- Analytics & Population-Health Platforms
- Clinical Decision Support
- Risk Stratification
- Mobile Apps & Patient Engagement Tools (mHealth)
- Integration & EHR Connectors
- Services
- Disease Management Programs
- Remote Monitoring Services
- Consulting & Implementation
- Training & Support
By Deployment Type
- Cloud-based
- On-premises
- Hybrid
By Indication
- Diabetes Mellitus
- Cardiovascular Diseases
- Heart Failure
- Hypertension
- Coronary Artery Disease
- Chronic Kidney Disease
- Oncology
- Mental Health
- Depression
- Anxiety
- Chronic Behavioral Health Comorbidity
By Technology
- Wearables & Connected Devices
- IoT & Sensors
- AI / ML & Predictive Analytics
- Clinical Decision Support
- Mobile Apps & SMS Platforms
By End User
- Ambulatory Care Centers
- Hospitals, Physician Groups & Integrated Delivery Networks
- Home Healthcare Agencies
- Nursing Homes & Assisted Living Facilities
- Diagnostic & Imaging Centers
- Pharmaceutical & Medtech Companies
- Public Payers
- Private Insurers
- Employer-Sponsored Funding
Impact of Artificial Intelligence on the Europe Chronic Disease Management Market
- Predictive Risk Stratification & Population Segmentation: AI/ML models analyze combined EHR, claims, and wearable data to segment populations by risk of hospitalization, complications, or cost, enabling targeted care management resources.
- Personalized Intervention & Dynamic Care Pathways: ML algorithms tailor patient education, behavioral nudges, and treatment suggestions in real-time by learning from outcomes of similar patient cohorts, moving beyond static care plans.
- Proactive Alerting for Clinical Deterioration: AI-powered monitoring of RPM data streams detects subtle, early signs of clinical decline (e.g., in heart failure or COPD) before patients become symptomatic, enabling timely intervention.
- Intelligent Clinical Decision Support: AI-enhanced CDS integrates latest guidelines and real-world evidence to suggest optimal medication adjustments or diagnostic steps to clinicians during virtual or in-person consultations.
- Optimization of Resource Allocation & Program ROI: AI analyzes program data to identify which interventions are most effective for specific patient subgroups, helping payers and providers optimize service design and maximize return on investment.
By Region
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Europe Chronic Disease Management Market: Competitive Landscape
The competitive landscape of the Europe chronic Disease Management market is dynamic and moderately fragmented, characterized by diverse players from adjacent sectors converging on digital health. Established Medtech & Health IT Giants like Philips and Siemens Healthineers leverage their deep clinical relationships, hardware portfolios (e.g., monitoring devices), and enterprise software expertise to offer integrated solutions. Specialized Digital Health & DTx Providers (e.g., players focused on diabetes, mental health) compete with best-in-class, indication-specific applications known for superior user engagement and clinical evidence.
Hyperscale Cloud Providers (AWS, Google, Microsoft) play a dual role as infrastructure partners and increasingly as platforms offering healthcare-specific AI/ML and data analytics services, upon which many CDM solutions are built. Telecom and Tech Integrators are also entering, providing connectivity and integration services for remote care. Competition is intensifying around who can best deliver interoperability, proven outcomes, and a seamless user experience for both clinicians and patients.
Some of the prominent players in the Europe Chronic Disease Management Market are
- Philips
- Siemens Healthineers
- ResMed
- Omada Health
- Livongo (Teladoc Health)
- Welldoc
- DarioHealth
- mySugr (Roche)
- Ada Health
- Kaia Health
- Amazon Web Services
- Google Cloud
- Microsoft Azure
- IBM
- Oracle Cerner
- Epic Systems
- Allscripts (Veradigm)
- GetReal Labs
- Huma
- Other Key Players
Recent Developments in the Europe Chronic Disease Management Market
- November 2025: Leading European health insurer Allianz Partners and digital therapeutics provider Huma Therapeutics announced a pan-European partnership to offer prescribed DTx for Type 2 Diabetes and Hypertension as a standard benefit within corporate health plans, signaling a major step in reimbursement integration and scaled access.
- October 2025: At the Frontiers Health 2025 conference in Berlin, CDM vendors Ada Health and Kaia Health unveiled new AI co-pilot features for clinicians. These tools are designed to automate clinical documentation from remote monitoring data streams and suggest real-time care plan adjustments during telehealth visits, reducing administrative burden.
- September 2025: DMEA 2025 saw the launch of several interoperability-focused CDM platforms, including Siemens Healthineers' next-generation teamplay ecosystem and Cureosity's novel platform, both claiming seamless FHIR-based integration with major European EHR systems like Cerner and CompuGroup Medical, directly addressing a key market restraint.
- September 2025: A consortium of university hospitals, including Assistance Publique – Hôpitaux de Paris (AP-HP) and Charité – Universitätsmedizin Berlin, initiated a joint procurement for a unified oncology survivorship and chronic care management platform, aiming to standardize digital follow-up care pathways across borders.
- August 2025: Global pharmaceutical company Novo Nordisk partnered with CDM platform vendor Welldoc to bundle a connected drug delivery device with a companion patient management app and clinician dashboard for a new GLP-1 therapy, creating an integrated, value-added service model.
- December 2024: Royal Philips acquired Cardiologs, a company specializing in AI-powered clinical deterioration prediction algorithms from ECG data, enhancing its RPM portfolio's capability to provide early warnings for conditions like sepsis and heart failure decompensation.
- May 2024: Siemens Healthineers expanded its teamplay digital health platform with a new module developed in collaboration with Relyens, focusing on integrated cardio-renal-metabolic (CRM) care, addressing the complex comorbidity of heart failure, kidney disease, and diabetes.
- May 2024: Google Cloud achieved broader CE marking as a Medical Device under the EU MDR for specific healthcare AI tools within its Vertex AI platform, facilitating their direct, regulated use in clinical decision support modules within European CDM applications
Report Details
| Report Characteristics |
| Market Size (2025) |
USD 1.3 Mn |
| Forecast Value (2034) |
USD 3.7 Mn |
| CAGR (2025–2034) |
11.9% |
| Historical Data |
2019 – 2024 |
| Base Year |
2024 |
| Estimate Year |
2025 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors, etc. |
| Segments Covered |
By Offering (Solutions, Services), By Deployment Type (Cloud-based, On-premises, Hybrid), By Indication (Diabetes Mellitus, Cardiovascular Diseases, Respiratory Diseases, Chronic Kidney Disease, Oncology, Mental Health, Other Indications), By Technology (Wearables & Connected Devices, IoT & Sensors, AI/ML & Predictive Analytics, Clinical Decision Support, Mobile Apps & SMS Platforms), By End User (By Providers, By Payer) |
| Regional Coverage |
Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe |
| Prominent Players |
Philips, Siemens Healthineers, ResMed, Omada Health, Livongo (Teladoc Health), Welldoc, DarioHealth, mySugr (Roche), Ada Health, Kaia Health, Amazon Web Services, Google Cloud, Microsoft Azure, IBM, Oracle Cerner, Epic Systems, Allscripts (Veradigm), GetReal Labs, Huma, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days, and 5 analysts working days respectively. |
Contents